Cetrorelix acetate

PreclinicalSmall molecule

Merck & Co.

Cetrorelix acetate is one of 34 small molecule programs targeting Testosterone. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TestosteroneUnknown status

RandomizedCompleted

TestosteronePreclinical

Unknown status

RandomizedPreclinical

Completed

Competition

Competitive Landscape

40 competitors in Randomized

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Phase 3

3 2

Tricor

JJagotec

Phase 3

2 3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 4

Methylthioninium Chloride

PProvepharm SAS

Phase 3

1 5

Yondelis

AApotex Inc.

Phase 3

1 6

Zytiga

Johnson & Johnson

Phase 2

2 7

Rituxan

Roche

Phase 2

2 8

Erleada

Johnson & Johnson

Phase 2

1 9

Jaypirca

Eli Lilly

Phase 2

1 10

Clomid

Ferring

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Infertility

NCT07340827

Clinical

Trials by Indication[1]

Testosterone1 trial

Testosterone and Neurovascular Control in Humans

Unknown status·WWestern University, Canada·N/A·NCT04819204·20 enrolled

Randomized1 trial

Gonadotropin-releasing Hormone Antagonist on Triggering Day: A Randomized Controlled Study

Completed·SSeoul National University Bundang Hospital·N/A·NCT00571870·80 enrolled

Frozen Embryo Transfer1 trial

Frozen Embryo Transfer With GnRH-antagonist Trial

Unknown status·UUniversity of Oxford·Phase 4·NCT03763786·300 enrolled

Assisted Reproductive Technology1 trial

Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01185704·136 enrolled

GAN1 trial

Cetrorelix and Ganirelix Flexible Protocol for (IVF)

Unknown status·—·Phase 4·NCT03477929·100 enrolled

3 more indications

Outcome1 trial

Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes

Unknown status·—·Phase 3·NCT05972902·387 enrolled

Progesterone1 trial

Patients' Preference for Subcutaneous or Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles

Terminated·AAndros Day Surgery Clinic·Phase 4·NCT03181685·60 enrolled

Infertility1 trial

A Parallel-group Treatment, 2-arm Study to Compare the Efficacy and Safety of Follitropin Alfa and Lutropin Alfa Fixed Dose Combination Versus hMG for Inducing Follicular Development in Japanese Participants With LH and FSH Deficiency Undergoing ART

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07340827·266 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Cetrorelix acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cetrorelix acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cetrorelix acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Merck & Co.

Cetrorelix acetate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Testosterone1 trial

Randomized1 trial

Frozen Embryo Transfer1 trial

Assisted Reproductive Technology1 trial

GAN1 trial

Outcome1 trial

Progesterone1 trial

Infertility1 trial

References

Drug Info

Quick Facts

Related News